Neurogene (NGNE) Stock Overview
A clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NGNE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Neurogene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.07 |
| 52 Week High | US$37.27 |
| 52 Week Low | US$6.88 |
| Beta | 1.99 |
| 1 Month Change | -1.81% |
| 3 Month Change | 15.31% |
| 1 Year Change | -11.27% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 32.91% |
Recent News & Updates
Neurogene: From Speculation To Execution With NGN-401
Nov 24We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth
Aug 13
Recent updates
Neurogene: From Speculation To Execution With NGN-401
Nov 24We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth
Aug 13Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401
Mar 07Neurogene: Interesting CNS Disease Company, Data Coming Soon
Nov 10Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers
Mar 26Shareholder Returns
| NGNE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.9% | 2.6% | 2.6% |
| 1Y | -11.3% | 25.9% | 14.2% |
Return vs Industry: NGNE underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: NGNE underperformed the US Market which returned 14.2% over the past year.
Price Volatility
| NGNE volatility | |
|---|---|
| NGNE Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NGNE's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NGNE's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 107 | Rachel McMinn | www.neurogene.com |
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University.
Neurogene Inc. Fundamentals Summary
| NGNE fundamental statistics | |
|---|---|
| Market cap | US$310.88m |
| Earnings (TTM) | -US$85.13m |
| Revenue (TTM) | n/a |
Is NGNE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGNE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$69.72m |
| Gross Profit | -US$69.72m |
| Other Expenses | US$15.41m |
| Earnings | -US$85.13m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NGNE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 23:19 |
| End of Day Share Price | 2025/12/24 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neurogene Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |
| Mani Foroohar | Leerink Partners LLC |